Hormone therapy (HT) for menopause — also called hormone replacement therapy or HRT — refers to the use of estrogen, with or without a progestogen, to address the hormonal deficiency of menopause. Estrogen is the primary driver of both the symptom burden of menopause — hot flashes, night sweats, vaginal dryness, sleep disruption, mood changes — and the long-term health consequences of estrogen deficiency, including bone loss and genitourinary atrophy. Replacing the estrogen that the ovaries no longer produce addresses both of these domains simultaneously.
A progestogen (progesterone or a synthetic progestin) is added to hormone therapy for women who have a uterus to protect the uterine lining from the stimulatory effect of unopposed estrogen. Women who have had a hysterectomy can use estrogen alone, without the added progestogen.
Hormone therapy is the most effective treatment available for hot flashes, night sweats, vaginal dryness, and the genitourinary changes of menopause. It is also the only treatment that specifically addresses the bone density loss that accelerates after menopause. For the right candidates — healthy women under 60 who are within 10 years of menopause onset — current evidence supports hormone therapy as safe and effective, with benefits that outweigh risks for most in this group.
Hormone therapy is not a single treatment — it is a range of formulations, routes of delivery, and combinations that are individualized based on the patient’s uterine status, symptom profile, and health history. Understanding the options is the starting point for an informed decision.
Estrogen-Only Therapy — For Women Who Have Had a Hysterectomy
Women who have had a hysterectomy do not have a uterus to protect and can take estrogen alone without a progestogen. Estrogen-only therapy provides the full symptom relief and health benefits of estrogen without the additional considerations associated with progestogen. It is available in multiple forms — oral tablets, transdermal patches, gels, sprays, and vaginal rings — and is selected based on patient preference and clinical considerations regarding route of delivery.
Combined Estrogen-Progestogen Therapy — For Women With a Uterus
Women who have a uterus require a progestogen alongside estrogen to prevent endometrial hyperplasia — excessive thickening of the uterine lining that can develop with unopposed estrogen stimulation. The progestogen component can be delivered as oral micronized progesterone (Prometrium), a synthetic progestin, or via a hormonal IUD (levonorgestrel) as an intrauterine progestogen that provides uterine protection while the systemic estrogen is delivered transdermally. The specific combination, type, and dosing of progestogen are selected based on individual health considerations.
Transdermal vs. Oral Estrogen — Why the Route of Delivery Matters
Oral estrogen is metabolized through the liver before entering systemic circulation (first-pass hepatic metabolism), which increases production of clotting factors and may increase venous thromboembolism (VTE) risk. Transdermal estrogen — delivered through patches, gels, or sprays directly into the bloodstream — bypasses first-pass hepatic metabolism and does not carry the same VTE risk elevation. Current evidence suggests that transdermal estrogen has a more favorable risk profile than oral estrogen for most patients, particularly those with cardiovascular risk factors. Dr. Andrei discusses route of delivery as part of the individualized hormone therapy conversation.
Local vs. Systemic Hormone Therapy
Systemic hormone therapy delivers estrogen into the bloodstream at levels sufficient to address hot flashes, sleep, mood, and bone health in addition to genitourinary symptoms. Local vaginal estrogen delivers very low doses directly to the vaginal and urethral tissue, addressing genitourinary syndrome of menopause — vaginal dryness, urinary urgency, dyspareunia — with minimal systemic absorption. Local vaginal estrogen is appropriate for women whose primary concern is genitourinary symptoms and who do not need systemic treatment for vasomotor symptoms. It has a very favorable safety profile and is appropriate even for women with a history of estrogen-sensitive cancers in many cases — though this requires individual clinical discussion.
Micronized Progesterone vs. Synthetic Progestins
Micronized progesterone (Prometrium) is a bioidentical progesterone — chemically identical to the progesterone produced by the body. It has a more favorable safety profile than some synthetic progestins, with evidence suggesting lower breast cancer risk association compared to certain progestins when used in combined hormone therapy. It also has favorable effects on sleep quality in some patients. Synthetic progestins are used in many combined oral contraceptives and some HRT formulations. The type of progestogen used in hormone therapy is part of the individualized treatment decision at Lapeer Women’s Health.
Hormone therapy is individualized medicine. No recommendation about hormone therapy should be made without a thorough review of your personal health history, including:
- Personal history of breast cancer, endometrial cancer, or other hormone-sensitive cancers
- Personal history of blood clots (DVT or pulmonary embolism)
- Personal history of stroke or cardiovascular disease
- Current medications that may interact with hormone therapy
- Uterine status — whether you have had a hysterectomy
The evidence base for hormone therapy has evolved substantially since the Women’s Health Initiative (WHI) in the early 2000s. Understanding what the WHI showed, what it did not show, and how subsequent research has refined the picture is essential to an informed discussion.
The WHI — What It Actually Found
The Women’s Health Initiative, published in 2002, found increased risks of breast cancer, stroke, and blood clots in women taking combined oral conjugated equine estrogen plus medroxyprogesterone acetate (a synthetic progestin). These findings generated widespread concern and led to a dramatic reduction in hormone therapy use. However, critical limitations of the WHI are essential to understanding its findings: the average participant was 63 years old — more than a decade past menopause onset — and two-thirds were overweight or obese. The WHI was not a study of healthy women in early menopause seeking symptom management. It was a study of older women being enrolled for the first time on hormone therapy in the hopes of cardiovascular prevention, which is not what hormone therapy is indicated for.
The Timing Hypothesis — Why When You Start Matters
Subsequent analysis of the WHI data and other large studies has established what is now called the “timing hypothesis” or “critical window” of hormone therapy. Women who begin hormone therapy within 10 years of menopause onset or before age 60 — the window during which most women seek treatment for symptoms — have a substantially more favorable risk profile than women who start later. The cardiovascular risks identified in the WHI appear to reflect the effects of estrogen on already-established atherosclerotic disease in older women, rather than an inherent risk of estrogen in younger, healthier menopausal women. This distinction is central to current hormone therapy guidance.
Breast Cancer Risk — A Nuanced Picture
The breast cancer risk associated with hormone therapy depends significantly on the type and duration of therapy. Estrogen-only therapy in women who have had a hysterectomy is not associated with increased breast cancer risk — and in the WHI, was actually associated with a modest reduction in breast cancer incidence. Combined therapy with synthetic progestins carries a small absolute increase in breast cancer risk with prolonged use. Combined therapy with micronized progesterone has a more favorable risk profile than synthetic progestins in this regard. The absolute risk increase from hormone therapy for most users is small in absolute terms — comparable to other modifiable lifestyle risk factors — and must be weighed against the substantial quality-of-life benefits and the benefits for bone and potentially cardiovascular health.
Benefits of Hormone Therapy Beyond Symptom Relief
Hormone therapy provides benefits that extend beyond vasomotor and genitourinary symptom management. It is the most effective available agent for preventing the accelerated bone density loss of the early postmenopausal years, reducing fracture risk. It may reduce cardiovascular risk when started in the early menopausal window. It is associated with reduced risk of type 2 diabetes. Some evidence suggests potential benefits for cognitive function when started in the early menopausal transition. These additional benefits strengthen the benefit-risk balance for eligible candidates and are part of the comprehensive hormone therapy discussion at Lapeer Women’s Health.
The bottom line from current professional society guidance — including from the North American Menopause Society, the Menopause Society, and the British Menopause Society — is that hormone therapy is appropriate and beneficial for most healthy women under 60 within 10 years of menopause onset who are experiencing significant symptoms, and that the historical overcorrection away from hormone therapy has left many women unnecessarily undertreated.
Hormone therapy counseling at Lapeer Women’s Health is led by Dr. Ramona D. Andrei, MD, PhD, FACOG — with a commitment to evidence-based individualized recommendations and a full, transparent discussion of benefits, risks, and alternatives.
Step 1 — Comprehensive Health History Review
Dr. Andrei reviews your symptom burden, menopausal stage, personal and family health history including breast health and cardiovascular history, current medications, and your goals for treatment. This review is the foundation of the individualized benefit-risk assessment that informs the hormone therapy recommendation.
Step 2 — Evidence-Based Discussion
Dr. Andrei presents the current evidence on hormone therapy clearly and specifically for your situation — including the type of therapy, route of delivery, and formulation most appropriate for your health profile. The discussion includes benefits, risks, non-hormonal alternatives, and what monitoring looks like during therapy.
Step 3 — Individualized Prescription and Follow-Up
If hormone therapy is appropriate and you choose to proceed, the prescription is specific to your clinical situation — not a generic formulation. Follow-up is scheduled to assess symptom response, adjust dosing if needed, and review any emerging considerations. Ongoing monitoring is a standard part of hormone therapy management at Lapeer Women’s Health.
Many women were told a decade or more ago that hormone therapy was dangerous and were advised to stop or to never start. That guidance was based on a reading of the WHI evidence that has since been substantially revised. For many of those women, the years since have involved unnecessary suffering from undertreated symptoms — or continued confusion about what current evidence actually says.
A conversation about hormone therapy in 2026 is a different conversation than it was in 2005. The evidence is clearer. The options are broader. And the individualized approach — matching the right formulation to the right patient at the right time — is what makes hormone therapy safe and effective for the women who are appropriate candidates for it.
Dr. Ramona D. Andrei and the team at Lapeer Women’s Health are here for that updated conversation — at both our Lapeer and Rochester Hills offices, without a referral required.
Hormone Therapy
Our team at Lapeer Women’s Health provides individualized, evidence-based HRT counseling at both our Lapeer and Rochester Hills offices. No referral required.
Schedule a Gynecologic VisitThe information on this page is intended for educational purposes only and does not constitute medical advice. Individual symptoms, diagnoses, and treatment options vary significantly. Reading this content does not establish a physician-patient relationship with Dr. Ramona D. Andrei or Lapeer Women’s Health. Content reviewed by Dr. Ramona D. Andrei, MD PhD FACOG.
Gynecologic care for women of every age
Lapeer Women’s Health — Rochester Hills
2710 S Rochester Rd, Suite 2
Rochester Hills, MI 48307
Serving patients in Lapeer, Rochester Hills, and surrounding communities throughout Southeast Michigan.